Alaunos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $4.42 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2014-03-03
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2013 was $4.42, a 1.84% increase from fiscal 2012.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2012 was $4.34, a 52.28% increase from fiscal 2011.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2011 was $2.85, a 35.23% decline from fiscal 2010.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2010 was $4.40.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2013-12-31 | $4.42 10-K · filed 2014-03-03 | ||
| 2012-12-31 | $4.34 10-K · filed 2014-03-03 | ||
| 2012-09-30 | $4.34 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $4.41 10-Q/A · filed 2012-08-28 | ||
| 2011-12-31 | $2.85 10-K · filed 2014-03-03 | ||
| 2010-12-31 | $4.40 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |